TrialNature medicine2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.
Benjamin Besse et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it
TrialNature medicine2026
Benjamin Besse et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.